These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35471992)

  • 1. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    Fu J; Gao Y; Shi L
    PLoS One; 2022; 17(4):e0267647. PubMed ID: 35471992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
    Wang Z; Chu P; Wang W
    Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
    Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
    Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.
    Ahmed Z; Hassan M; Arif SF; Aziz M; Iqbal U; Nawaz A; Farooq U; Smith WL; Badal J; Renno A; Javaid T; Nawras A; Saab S
    J Gastrointestin Liver Dis; 2023 Apr; 32(1):70-76. PubMed ID: 37004220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
    J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
    Volk ML; Burne R; Guérin A; Shi S; Joseph GJ; Heimanson Z; Ahmad M
    J Med Econ; 2021; 24(1):202-211. PubMed ID: 33464935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
    Neff G; Zachry W
    Pharmacoeconomics; 2018 Jul; 36(7):809-822. PubMed ID: 29651649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
    Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
    Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    Tapper EB; Essien UR; Zhao Z; Ufere NN; Parikh ND
    J Hepatol; 2022 Aug; 77(2):377-382. PubMed ID: 35367057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
    Cheng J; Chen Y; Cao W; Zuo G
    Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
    Hammd M; Elghezewi A; Abdulhadi A; Alabid A; Alabid A; Badi Y; Kamal I; Hesham Gamal M; Mohamed Fisal K; Mujtaba M; Sherif A; Frandah W
    Cureus; 2024 Jan; 16(1):e53341. PubMed ID: 38435950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.